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Elevation of Creatine Kinase, MB
Fraction After Elective Coronary
Intervention: A Valid Surrogate
End Point of Poor Late Outcome?*
Guy S. Reeder, MD
Rochester, Minnesota
Over the last decade, a substantial body of evidence that is
predominately observational and usually associated with the
evaluation of new devices and drugs has characterized the
circumstances and outcomes of periprocedural elevation of
creatine kinase, MB fraction (CK-MB). Most, but not all,
studies could be summarized as follows:
c Release of CK-MB is common if sought for in up to 25%
of cases of percutaneous intervention; most commonly ,5
times the upper limit of normal.
c The causes may include angiographically evident events,
such as branch vessel occlusion or embolization, but just
as often they may be neither symptomatic or angiographi-
cally apparent.
c The likelihood of enzyme release is greater with nonbal-
loon devices, such as rotablator, directional atherectomy
and stents.
c Enzyme release is correlated with late mortality in some
studies.
c The exact level of enzyme elevation to diagnose “myocar-
dial infarction” with its attendant clinical and economic
implications for patient management is uncertain, al-
though an upper level of three times normal has been
suggested (1).
In this issue of the Journal, Kini et al. (2) found CK-MB
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elevation in nearly 19% of 1,675 patients undergoing elec-
tive percutaneous coronary intervention. A procedural cause
was identifiable in less than one-half of the patients. During
the mean follow-up of 13 6 3 months, there was only a
nonsignificant trend (1.6% vs. 1.3%) in increased mortality
for all patients with CK-MB elevation, and no adverse
in-hospital events in those with ,5 times normal elevation.
On multivariate analysis, predictors of CK-MB elevation
included severity of coronary and systemic atherosclerosis,
stenting and absence of beta-adrenergic blocking agent
therapy.
A recently reported preliminary analysis of over 7,000
consecutive elective percutaneous interventions showed
similar findings, with only a weak trend toward worse
outcome with ,5 times normal enzyme elevations, but
there was a high association between late mortality and
other comorbidities by multivariate analysis (3). These
findings emphasize two critical issues that remain contro-
versial:
c At what enzyme level should a diagnosis of “periproce-
dural myocardial infarction” be made?
c Are modest elevations (,5 times normal) of CK-MB
simply a correlate (i.e., a surrogate marker related to the
extent of disease) (4) or are they somehow causative of
subsequent adverse events, including mortality?
Traditionally defined myocardial infarction usually
evolves from an occluded artery, resulting in left ventricular
dysfunction, the extent of which is a strong predictor of
postinfarct survival, and recurrent events, including mortal-
ity, occur relatively early, often in one to two months after
infarction. The cardiac enzyme elevations of ,5 times
normal, which most commonly occur after percutaneous
coronary intervention, are often not associated with an
occluded vessel, do not produce significant left ventricular
dysfunction and have usually been associated (in positive
studies) with late mortality (5). The mechanism of late
death has not been defined. It has been suggested that
“microinfarcts,” which manifest as enzyme release during
percutaneous coronary interventions, might predispose to
late arrhythmic events. This is highly unlikely, given the
large body of evidence showing that malignant ventricular
arrhythmias are predominantly confined to patients with a
large infarction, substantial left ventricular systolic dysfunc-
tion (ejection fraction ,40%), left ventricular enlargement
and postinfarct remodeling. If enzyme release is causally
related to late mortality, a reduction in enzyme release
should reduce mortality. However, the substantial reduction
in periprocedural CK-MB elevation by glycoprotein IIb/
IIIa platelet receptor antagonists has generally resulted in
only a nonsignificant trend toward reduced mortality, sug-
gesting that enzyme elevation is correlated with but may not
be causative of late outcome, at least at modest levels. In a
meta-analysis of 16 randomized, controlled trials of glyco-
protein IIb/IIIa agents in over 32,000 patients, no signifi-
cant mortality difference at 30 days or 6 months could be
documented (6). (Only one trial, EPISTENT, preliminarily
reported at the February 1999 meeting of the American
College of Cardiology (7), showed a 1% absolute mortality
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reduction for the combination of abciximab and stenting vs.
stenting alone. There was no mortality reduction from
abciximab, however, in nonstented patients.)
The study by Kini et al. (2) adds to the controversy
regarding periprocedural CK-MB elevation and subsequent
coronary events. What are the clinical implications of this
report? One may hypothesize that the limits for dismissal of
patients with elevated periprocedural CK-MB may be
extended to five times normal in the absence of high risk
clinical factors. Prospective validation of this hypothesis
will be needed. Further studies are also needed to
establish the mechanism of death in those investiga-
tions that have shown a correlation between mortality
and modest elevation of CK-MB. All patients, especially
those with enzyme elevation, should have long-term
risk reduction with agents proven to prolong survival
in coronary artery disease: aspirin, beta-blockers,
angiotensin-converting enzyme inhibitors and statins.
Longer follow-up periods of studies correlating CK-MB
release with mortality are warranted.
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